These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 10864101)

  • 41. Behavioural sensitization in mice induced by morphine-glucuronide metabolites.
    Handal M; Ripel A; Skurtveit S; Mørland J
    Pharmacol Biochem Behav; 2008 Oct; 90(4):578-85. PubMed ID: 18555521
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Altered drug disposition of the platelet activating factor antagonist apafant in mdr1a knockout mice.
    Leusch A; Volz A; Müller G; Wagner A; Sauer A; Greischel A; Roth W
    Eur J Pharm Sci; 2002 Aug; 16(3):119-28. PubMed ID: 12128165
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Morphine-6-glucuronide: a potent stimulator of locomotor activity in mice.
    Mørland J; Jones BL; Palomares ML; Alkana RL
    Life Sci; 1994; 55(8):PL163-8. PubMed ID: 8046991
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration.
    Wolff T; Samuelsson H; Hedner T
    Pain; 1995 Aug; 62(2):147-154. PubMed ID: 8545139
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sex-dependent influences of morphine and its metabolites on pain sensitivity in the rat.
    Doyle HH; Murphy AZ
    Physiol Behav; 2018 Apr; 187():32-41. PubMed ID: 29199028
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of morphine glucuronides on the function of opioid receptors in human SK-N-SH cells.
    Baker L; Dye A; Ratka A
    Neurosci Lett; 2000 Mar; 281(1):1-4. PubMed ID: 10686401
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine.
    Klepstad P; Kaasa S; Borchgrevink PC
    Eur J Clin Pharmacol; 2000 Jan; 55(10):713-9. PubMed ID: 10663448
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine.
    Stuart-Harris R; Joel SP; McDonald P; Currow D; Slevin ML
    Br J Clin Pharmacol; 2000 Mar; 49(3):207-14. PubMed ID: 10718775
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Day-to-day variations during clinical drug monitoring of morphine, morphine-3-glucuronide and morphine-6-glucuronide serum concentrations in cancer patients. A prospective observational study.
    Klepstad P; Hilton P; Moen J; Kaasa S; Borchgrevink PC; Zahlsen K; Dale O
    BMC Clin Pharmacol; 2004 Oct; 4():7. PubMed ID: 15461818
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of a Noninvasive Brain-Penetrating Peptide-Drug Conjugate Strategy to Improve the Delivery of Opioid Pain Relief Medications to the Brain.
    Eiselt É; Otis V; Belleville K; Yang G; Larocque A; Régina A; Demeule M; Sarret P; Gendron L
    J Pharmacol Exp Ther; 2020 Jul; 374(1):52-61. PubMed ID: 32327529
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The spinal antinociceptive actions of morphine metabolites morphine-6-glucuronide and normorphine in the rat.
    Sullivan AF; McQuay HJ; Bailey D; Dickenson AH
    Brain Res; 1989 Mar; 482(2):219-24. PubMed ID: 2706485
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Morphine-6-glucuronide: analgesic effects and receptor binding profile in rats.
    Abbott FV; Palmour RM
    Life Sci; 1988; 43(21):1685-95. PubMed ID: 2848167
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1.
    Schuller AG; King MA; Zhang J; Bolan E; Pan YX; Morgan DJ; Chang A; Czick ME; Unterwald EM; Pasternak GW; Pintar JE
    Nat Neurosci; 1999 Feb; 2(2):151-6. PubMed ID: 10195199
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats--pharmacokinetic/pharmacodynamic modelling.
    Bouw MR; Xie R; Tunblad K; Hammarlund-Udenaes M
    Br J Pharmacol; 2001 Dec; 134(8):1796-804. PubMed ID: 11739257
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Further evidence that morphine-6 beta-glucuronide is a more potent opioid agonist than morphine.
    Frances B; Gout R; Monsarrat B; Cros J; Zajac JM
    J Pharmacol Exp Ther; 1992 Jul; 262(1):25-31. PubMed ID: 1320685
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
    Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
    J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of 12-oxochenodeoxycholate on the pharmacokinetics and pharmacodynamics of morphine 6-glucuronide in Wistar rats.
    Yang L; Fawcett JP; Zhang H; Tucker IG
    J Pharm Pharmacol; 2013 Apr; 65(4):561-6. PubMed ID: 23488785
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.
    Drewe J; Ball HA; Beglinger C; Peng B; Kemmler A; Schächinger H; Haefeli WE
    Br J Clin Pharmacol; 2000 Sep; 50(3):237-46. PubMed ID: 10971308
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changing M3G/M6G ratios and pharmacodynamics in a cancer patient during long-term morphine treatment.
    Andersen G; Christrup LL; Sjøgren P; Hansen SH; Jensen NH
    J Pain Symptom Manage; 2002 Feb; 23(2):161-4. PubMed ID: 11844638
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain.
    De Gregori S; Minella CE; De Gregori M; Tinelli C; Ranzani GN; Govoni S; Allegri M; Regazzi M
    Ther Drug Monit; 2014 Jun; 36(3):335-44. PubMed ID: 24595069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.